Athenex (NASDAQ:ATNX) Lifted to “Buy” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Athenex (NASDAQ:ATNX) from a hold rating to a buy rating in a research report report published on Thursday morning, BidAskClub reports.

Several other equities analysts also recently commented on the company. CIBC cut their price objective on Rocky Mountain Dealerships from C$10.50 to C$10.00 in a research report on Thursday, May 2nd. SunTrust Banks upped their price objective on Accenture to $180.00 and gave the company a hold rating in a research report on Friday, March 29th. They noted that the move was a valuation call. Zacks Investment Research raised DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. Oppenheimer cut their price objective on Littelfuse from $215.00 to $210.00 and set an outperform rating on the stock in a research report on Thursday, May 2nd. Finally, Royal Bank of Canada reaffirmed an outperform rating on shares of in a research report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $22.17.

Shares of Athenex stock opened at $19.98 on Thursday. The firm has a fifty day simple moving average of $17.25. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.85 and a current ratio of 2.22. Athenex has a 52 week low of $9.38 and a 52 week high of $21.11.

Athenex (NASDAQ:ATNX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.08). The business had revenue of $25.31 million during the quarter, compared to the consensus estimate of $19.55 million. Athenex had a negative net margin of 189.86% and a negative return on equity of 96.55%. On average, equities analysts expect that Athenex will post -1.73 EPS for the current fiscal year.

In other news, major shareholder Perceptive Advisors Llc bought 100,000 shares of the stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $12.71 per share, for a total transaction of $1,271,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jordan Kanfer bought 2,500 shares of the stock in a transaction on Thursday, June 6th. The stock was purchased at an average price of $15.01 per share, with a total value of $37,525.00. Following the completion of the acquisition, the director now directly owns 4,184 shares in the company, valued at approximately $62,801.84. The disclosure for this purchase can be found here. Insiders acquired a total of 318,210 shares of company stock valued at $5,111,581 over the last quarter. Company insiders own 18.80% of the company’s stock.

Hedge funds have recently modified their holdings of the business. First Trust Advisors LP purchased a new stake in Athenex during the 1st quarter worth about $1,054,000. DekaBank Deutsche Girozentrale lifted its holdings in Athenex by 21.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 22,900 shares of the company’s stock worth $366,000 after buying an additional 4,100 shares during the last quarter. Emory University purchased a new stake in shares of Athenex in the 1st quarter valued at about $2,312,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Athenex by 913,400.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,135 shares of the company’s stock valued at $112,000 after purchasing an additional 9,134 shares during the last quarter. Finally, Virginia Retirement Systems ET AL purchased a new stake in shares of Athenex in the 1st quarter valued at about $158,000. Institutional investors and hedge funds own 31.21% of the company’s stock.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Featured Story: Cash Flow

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.